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Heme oxygenase 1 (HO-1) is a representative mediator of
antioxidants and cytoprotectants against various stress stimuli
including oxidants in vascular cells. Intensive insulin treatment
can delay the onset and progression of diabetic retinopathy and
other vascularopathies, yet little is known about insulin regula-
tion of anti-apoptotic and antioxidant molecules such as HO-1
in vascular cells. Intravitreous injection or in vitro addition of
insulin increased HO-1 protein expression in rat retina and in
cultured bovine retinal pericytes, retinal endothelial cells, and
retinal pigment epithelial cells. In bovine retinal pericytes, insu-
lin induced mRNA and protein expression of HO-1 in a time-
and concentration-dependent manner. Using HO-1 promoter
analysis, the luciferase reporter assay showed that induction of
HO-1 expression by insulin is mediated by additional response
elements in the ho-1 promoter gene, which was not responsive
to antioxidants. Insulin-induced HO-1 mRNA expression
through activation of PI3-kinase/Akt pathway without affecting
ERK and p38MAPK. Overexpression of an adenoviral vector of
native IRS1, IRS2, and Akt dominant negative or small interfer-
ing RNA transfection of Akt1 and Akt2 targeted gene demon-
strated that insulin regulated HO-1 expression via IRS1 and
Akt2 pathway, selectively. Further, insulin treatment prevented
H2O2-induced NF-B and caspase-8 activation and apoptosis
via the IRS1/PI3K/Akt2/HO-1 pathway in the pericytes. In con-
clusion, we suggest that the anti-apoptotic properties of insulin
aremediated partly by increasingHO-1 expression at transcrip-
tional level via IRS1/PI3K/Akt2 activation, a potential explana-
tion for how insulin is retarding the progression of microvascu-
lar complications induced by diabetes.
Oxidative stress, as a result of hyperglycemia and diabetes,
has been postulated to be a major metabolic abnormality caus-
ing a variety of cellular dysfunctions and vascular pathologies
(1–3). Increases in oxidative stress in patients who have diabe-
tes with poor glycemic control or insulin resistance may result
from enhanced production of reactive oxygen species (ROS)3
because of metabolism of metabolites such as elevated glucose
and free fatty acid levels in excess of endogenous antioxidant
defense (4–6). Large clinical studies such as Diabetes Compli-
cations and Control Trial and the Epidemiology of Diabetes
Interventions and Complications trials have clearly identified
hyperglycemia as one of the main initiating factors of diabetic
complications that can be mitigated by insulin treatment in
type 1 diabetic patients (7, 8). One of the earliest and most
specific histopathological findings associated with hyperglyce-
mia and diabetic retinopathy is the selective loss of retinal cap-
illary pericytes, probably because of apoptosis (9).Many studies
have proposed that oxidative stress via elevation of glucose lev-
els is one of the potential triggers of the increased rate of peri-
cyte apoptosis (10, 11). Antioxidant treatments have been
reported to ameliorate diabetic retinopathy by preserving reti-
nal vascular pericytes in rodent models of diabetes (12). How-
ever, in large clinical studies, including the Heart Outcomes
Prevention Study, antioxidant treatments such as vitamins C
and E did not provide substantial improvement of microvascu-
lar or cardiovascular damage in individuals who had diabetes
for several years (13). Thus, it is possible that in addition to
normalizing hyperglycemia, insulin may directly affect the
endogenous antioxidant defense to neutralize the intracellular
elevation of oxidants induced by the metabolism of elevated
levels of glucose or free fatty acids.
Heme oxygenase (HO) plays an important key role in regu-
lating the intracellular heme level by catalyzing the initial and
rate-limiting step of heme degradation, in which oxidative
cleavage of the porphyrin ring results in formation of biliverdin,
CO, and free iron (14, 15). A number of studies have demon-
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strated the potent antioxidant activity of biliverdin and biliru-
bin and the cytoprotective action of CO on vascular cells (16).
To date, three isoforms of mammalian HO have been identi-
fied: HO-1, HO-2, andHO-3 (15, 17). Under physiological con-
ditions, HO-1, the inducible 32-kDa isoform, is highly
expressed in liver and spleen, whereas HO-2, the constitutive
36-kDa isoform, is expressedmainly in brain and testis. HO-3, a
33-kDa isoform that closely resemblesHO-2, has been detected
in many tissues including the spleen, liver, thymus, prostate,
heart, kidney, brain, and testis but has very low enzyme activity
compared with that of the other two isoforms (17). The HO-1
isozyme is a phase II enzyme, a member of the family of heat
shock proteins, and its expression is triggered by diverse stress
stimuli including hypoxia (18), heavy metals, UV radiation,
ROS such as H2O2 (19), reactive nitrogen oxides such as NO
(20), tumor necrosis factor-, interleukin-1, interferon- (21),
and phenolic compounds such as curcumin and caffeic acid
(22). The biological functions of HO-1 are thus believed to be
associated with a fundamental adaptive and defensive response
against oxidative and cellular stress. Indeed, inhibition of HO-1
by using HO inhibitors such as zinc protoporphyrin or tin pro-
toporphyrin resulted in a worsening of the diseases in which
these stresses operate, such as graft rejection, ischemia-reper-
fusion injury, cisplatin nephrotoxicity, and endotoxin-induced
septic shock (23). In contrast, HO-1 inducers, such as cobalt
protoporphyrin, and selective overexpression of HO-1 by
genetic manipulation produced beneficial effects in cultured
cells and in a variety of animal models of various diseases in
brain, heart, kidney, lung, and liver (23). Accumulating evi-
dence suggests a vital role for HO-1 in both cell growth and cell
death, especially involvement of the enzymes in the regulation
of apoptosis (24). Previous studies have also reported thatHO-1
can serve as a downstream effecter of interleukin-10 providing
evidence of potential anti-inflammatory approaches for treat-
ing diseases (25). Thus, HO-1 represents a crucial mediator of
antioxidants that comprises a key component of anti-inflam-
matory and anti-apoptotic stress defense mechanisms docu-
mented in various tissues including heart, kidney, and brain.
HO-1 has been described to be elevated in the myocardium,
glomeruli, and retina of diabetic animals as well as in diabetic
patients associated with insulin resistance (26–28). Recent
studies have shown increased expression of HO-1 attenuated
cytokine- and glucose-mediated cell growth arrest and apopto-
sis in vitro and decreased endothelial cell signaling in diabetes
rodent animals (29). Because intensive insulin treatment can
substantially decrease the progression of vascular disease, we
have characterized the effects of insulin on HO-1 expression
and actions as a possible antioxidative target. Despite the
increasing evidence that insulin has multiple actions on vascu-
lar cells, its effect on the regulation of HO-1 has not been stud-
ied in detail. In this study, we have evaluated the effect of insulin
on HO-1 expression and its actions in cultured BRPC and dis-
sected the signaling pathways leading to HO-1 regulation. Our
results indicate that insulin activates HO-1 expression by
increasing its promoter activity selectively by the IRS1/PI3K/
Akt2-dependent pathway.
EXPERIMENTAL PROCEDURES
Reagents—Fetal bovine serum (FBS), Dulbecco’s modified
Eagle’s medium (DMEM), and penicillin-streptomycin were
obtained from Invitrogen. Primary antibodies for immunoblot-
ting were obtained from commercial sources including anti-
actin and anti-BAX from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA), anti-caspase-8, anti-phospho-Bad, anti-IRS1, phos-
pho-Akt, phospho-ERKanti-Akt1, and anti-Akt2 fromCell Sig-
naling (Danvers, MA), polyclonal antibody against bovine
HO-1 and HO-2 from Stressgen Biotechnologies (Victoria,
Canada), anti-IRS2 from Millipore (Danvers, MA), and anti-
rabbit peroxidase-conjugated secondary antibody from GE
Healthcare. Zinc protoporphyrin was obtained from Porphyrin
Products (Logan, UT). PD98059, SB203580, wortmannin, and
LY294002 were purchased from Calbiochem. All other
reagents employed including bovine serum albumin (BSA)
(fraction V), 2,4,6-trinitrobenzenesulfonic acid, EDTA, hepa-
rin, leupeptin, phenylmethylsulfonyl fluoride, aprotinin, leu-
peptin, Na3VO4, andN-acetyl cysteine (20mM)were purchased
from Sigma-Aldrich, unless otherwise stated.
Cell Culture—Fresh calf eyes were obtained from a local
abattoir. Primary cultures of bovine retinal endothelial cells
(BREC) and pericyte cells (BRPC) were isolated by homogeni-
zation and a series of filtration steps as described previously
(30). Bovine retinal pigment epithelial cells (BRPE) were iso-
lated by gentle scraping after the removal of the neural retina
and incubation with 0.2% collagenase (31). BREC were subse-
quently propagated with DMEM and 10% FBS, 50 mg/liters
heparin, and 50 g/ml endothelial cell growth factor (Roche
Applied Science) and grown on collagen I-coated dishes (BD
Biosciences, San Jose, CA). BRPC were cultured in DMEM and
20% FBS and BRPE in DMEM and 10% FBS. The cells were
cultured in 5%CO2 at 37 °C, and themedia were changed every
other day. BREC and BRPC were characterized for homogene-
ity by immunoreactivity with anti-factor VIII antibody and
monoclonal antibody 3G5, respectively (32). The authenticity
of BRPE was verified by the presence of pigment granules on
transmission electron microscopy. BREC from passages 2–7,
and BRPC and BRPE from passages 2–5 were used in these
experiments. The cells remained morphologically unchanged
under these conditions, as confirmed by light microscopy.
Stock solution of hemin was prepared freshly in 0.05 N sodium
hydroxide. BRPCs were precultured respectively in DMEM
containing 0.1% BSA overnight before the induction of HO-1.
HO-1 expression was induced by adding 20 M hemin or dif-
ferent concentrations of insulin to the culture medium and
incubating at 37 °C for various time points.
Immunoblot Analyses—The cells were stimulated with the
compounds indicated after overnight starvation in 0.1% BSA.
The cells were lysed in Laemmli buffer (50 mM Tris, pH 6.8, 2%
SDS, and 10% glycerol) containing protease inhibitors (1 mM
phenylmethylsulfonyl fluoride, 2 g/ml aprotinin, 10 g/ml
leupeptin, 1 mM Na3VO4; Sigma). The protein amount was
measured with BCA kit (Bio-Rad). The lysates (50 g protein)
were separated by SDS-PAGE, transferred to polyvinylidene
difluoridemembrane, and blockedwith 5% skimmilk. Antigens
were detected using anti-rabbit horseradish peroxidase-conju-
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gated antibody for Western blot and detected with the ECL
system (GE Healthcare). Protein content quantification was
performed using computer-assisted densitometry (Image-
quant; GE Healthcare).
Real Time PCR Analyses—Real time PCR was performed to
evaluate mRNA expressions of HO-1 in cultured BRPC. Total
RNAwas extracted from cultured cells with TRI-REAGENT, as
described by the manufacturer and RNeasy mini kit (Qiagen).
The RNA was treated with deoxyribonuclease I (Invitrogen) to
remove any genomicDNA contamination. Approximately 1g
of RNAwas used to generate cDNAusing SuperScript II reverse
transcriptase and randomhexamers (Invitrogen) at 42 °C for 60
min. PCR primers and probes were: bovine HO-1 (GenBankTM
NM001014912), forward 5-CTTCTTCACTTTCCCCAATA-
3; reverse 5-TCATCTCCAGAGTGTTCATG-3; TaqMan
probe 56FAM-CGCCAGTGCCACCAAGTTCAAGCAGC-
TAMRA3. 18 S ribosomal RNA expression was used for nor-
malization. PCR products were gel-purified, subcloned using
QIA quick PCR Purification kit (Qiagen), and sequenced in
both directions to confirm identity.
Luciferase Reporter Constructs and Expression Plasmids—An
HO-1 luciferase reporter plasmid, HO-1-(4045/74), was
amplified from mouse genomic DNA by PCR and subcloned
into the pGL2 luciferase reporter vector (Promega, Madison,
WI). This HO-1 promoter was described previously (33).
HO-1-(3527/74), HO-1-(2986/74), HO-1-(2413/
74), HO-1-(1857/74), HO-1-(295/74), HO-1-
(137/74), HO-1-(117/74), HO-1-(66/74), and
HO-1-(35/74) deletion mutants were generated by PCR
amplification with HO-1-(4045/74) as the template.
Cell Transfection and Luciferase Assay—HO-1 reporter con-
structs were used for transient transfection assays of BRPCs
as described previously (34). Briefly, BRPCs were seeded on
60-mm cell culture plates. After 24 h of incubation, the cells
were 60–80% confluent. The BRPCs were cotransfected
with 0.2 g of luciferase expression plasmid and 0.05 g of
PRL-TK plasmid as normalization reference for transfection
efficiency, and 0.75 g of each expression plasmid using
Lipofectamine 2000 (Invitrogen) following the instructions
for the reagent. After 48 h transfection, the cells were har-
vested. The firefly and Renilla luciferase activities were
determined by using a dual luciferase reporter assay kit (Pro-
mega) with signal detection duration of 30 s by a luminom-
eter (Moonlight 3010; Analytical Luminescence Laboratory,
San Diego CA).
siRNA Transfection—The transfection of siRNA was per-
formed using theAmaxa basic nucleofactor kit for primary cells
(Amaxa Inc., Gaithersburg, MD) and following the Amaxa
guidelines. Briefly, the cells were resuspended in the basic
nucleofector solution. Cell suspension (100 l) at a density of
1–3 105/ml mixed with 2 g of pmax green fluorescent pro-
tein (GFP) vector plus 1l of 100M siRNAwere transferred to
a cuvette and nucleofected with an Amaxa nucleofector appa-
ratus. The cells were transfected using specific pulsing param-
eter and were immediately transferred into wells containing
37 °C prewarmed culture medium in 6-well plates. Untreated
cells and cells in nucleofector solution, without siRNA andwith
the application of the electroporation program, were both used
as negative controls. Twenty-four hours after the electropora-
tion, the cells were stimulatedwith insulin (100 nM) for 12 h and
then lysed for immunoblot analyses.
Adenoviral Vector Transfection—cDNA of native IRS1 and
IRS2 were generously gifted by Dr. Morris White and Dr. C.
Ronald Kahn’s laboratories, respectively. Dominant negative
Akt was constructed by substituting Thr-308 to Ala and Ser-
473 to Ala as described previously (35). Adenovirus was applied
at a concentration of 1  108 plaque-forming units/ml, and
adenovirus with the same parental genome carrying GFP or
LacZ gene was used as controls. Expression of each recombi-
nant protein was confirmed by Western blot analysis, and
expression was increased10-fold with all constructs as com-
pared with the cells infected with control adenovirus.
DNA Fragmentation Analysis—DNA fragmentation was
measured by quantitation of cytosolic oligonucleosome-bound
DNA using enzyme-linked immunosorbent assay (Roche
Applied Science) according to the manufacturer’s instructions.
Briefly, the cells were grown in 6-well plates at a density of 1
105 cells/well in 2 ml of DMEM and 20% FBS. After incubation
with insulin (24 h) and/or H2O2 (1 h), the cells were lysed
directly on the plate. The cytosolic fraction was used as antigen
source in a sandwich enzyme-linked immunosorbent assay
with primary anti-histone antibody coated to the microtiter
plate and a secondary anti-DNA antibody coupled to peroxi-
dase. From the absorbance values, the fragmentation in com-
parison with controls was calculated according to the following
formula: ratio of control  100  (absorbance stimulated
cells absorbance blank)/(absorbance control cells absorb-
ance blank).
Nuclear Extract and NoShift Transcription Factor Assay—
The cells were stimulated with the conditions and compounds
indicated after overnight starvation in 0.1% BSA. After stimu-
lation, the cells were washed three times with cold PBS and
lysed, and nuclear-specific proteins were isolated using the
NucBuster protein extraction kit (Novagen, Madison, WI)
according to the manufacturer’s instructions. Detection of
NF-B in the nucleus was quantified using the NoShift tran-
scription factor assay kit (Novagen). Briefly, 20 g of nuclear
protein was incubated with biotin-labeled wild-type DNA (10
pM) alone or in combination with 10-fold molar excess biotin-
labeled mutant DNA or cold wild-type DNA. The reactions
were added to streptavidin-coated plates and incubated for an
hour. The wells were washed three times and treated with pri-
mary antibody (anti-p65 subunit) for an hour. The wells were
then washed three times and exposed with the anti-mouse sec-
ondary antibody. After five washes, 3,5,5-tetramethyl benzi-
dine substrate was added, and the reaction was stopped after 15
min by the addition of 1 NHCL. The absorbancewas read at 450
nm (EL808; BIO-Tek Instruments, Inc., Highland Park, VT) to
quantify the nuclear NF-B levels.
Statistical Analysis—These data were shown as the means
S.D. for each group. Statistical analysis was performed by
unpaired t test or by one-way analysis of variance followed by
Tukey’s test correction for multiple comparisons. All of our
results were considered statistically significant at p 0.05.
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Insulin-inducedHO-1 Expression in Retinal Vascular Cells in
Culture and in Vivo—The effect of insulin on HO-1 expression
was characterized in several retinal cells because insulin can
regulate multiple biological actions in retinal endothelial cells
and pericytes (36, 37). In addition, various reports have shown
that insulin signaling in the retina is impaired in diabetes (38).
Therefore, the effect of insulin to modulate HO-1 expression
was studied in retinal vascular cells such as BRPC, BRPE, and
BREC.After overnight incubationwith 0.1%BSA, the cells were
treated with insulin (100 nM) for a period of 6 h or in the pres-
ence of low (5.6 mM) or high glucose concentration (HG; 25
mM) for 24 h (Fig. 1A). As compared with cells exposed to low
glucose, exposure to HG elevated HO-1 protein expression
only inBRECby 62% (p 0.05) but, surprisingly, not inBRPEor
BRPC. In contrast to HG exposure, insulin stimulation signifi-
cantly increased the protein expression of HO-1 in all retinal
cell types (BRPE 51%; BRPC 55%; BREC 40%; p 0.05)
(Fig. 1A). To confirm that the effect of insulin in increasing
HO-1 expression has physiological significance, insulin was
injected into the vitreous of Sprague-Dawley rats, increasing
HO-1 protein expression in the whole retina by 57% (p 0.02)
after 24 h as compared with saline-injected retina (Fig. 1B).
Time- and Concentration-dependent Effects of Insulin in
mRNA and Protein Expression of HO-1 in BRPC—Because
insulin increased HO-1 protein expression in several retinal
cells, we characterized the actions of insulin inBRPC,which has
been shown to be very sensitive to insulin. In addition, unlike
BREC and BRPE, pericyte apoptosis has been clearly demon-
strated to be a specific and consistent finding in diabetic reti-
nopathy (39). Insulin (100 nM) increased time-dependentHO-1
mRNA and protein expression with
maximum effect at 3 h (by 3-fold;
p  0.05) and 12 h (2.4-fold; p 
0.05), respectively (Fig. 2, A and B).
Using these time points, the dose-
response effect of insulin was also
evaluated. Insulin increased HO-1
mRNA and protein expression in a
dose-dependent manner with max-
imumeffect at 10 nMby 1.8- and 3.4-
fold (p  0.05), respectively (Fig. 2,
C and D). HO-2, which is constitu-
tively expressed in the cell, was not
affected by the addition of insulin
(Fig. 2, A and C) or hemin (data not
shown).
Insulin Regulates Transcriptional
Activity of HO-1—The effect of
insulin onHO-1 expressionwas fur-
ther examined to determine its
action on the transcriptional activi-
ties of HO-1. The results in Fig. 3A
show that the elevation of HO-1
mRNA expression by insulin was
completely prevented by using acti-
nomycin D (5 g/ml), an inhibitor
of transcription (p 0.05). Further,
the effect of insulin to modulate the transcriptional level of
HO-1 was characterized by measuring insulin action on the
promoter activity of HO-1-(4045/74) luciferase reporter
construct. We observed that insulin increased HO-1 promoter
activity by 3-fold (p 0.05) (Fig. 3B). These results suggest that
insulin can increaseHO-1 transcription bymodulating the pro-
moter activity in the 5 sequence region of HO-1.
Insulin-responsive Element Is Located Downstream of bp
2986 in the HO-1 Promoter—To characterize the promoter
region targeted by insulin, we analyzed the various constructs,
which contained several lengths of the 5 DNA sequence of
HO-1 that have been reported inmacrophage (33). The respon-
siveness of HO-1 construct covering4045/74 base of the 5
region of HO-1 to insulin (100 nM) and H2O2 were evaluated.
Both insulin and H2O2 were able to increase luciferase activa-
tion by 2.9- and 3.1-fold (p 0.05) as compared with basal (Fig.
4). To further localize the insulin-responsive element, several
sequential deletionmutants ofHO-1-(4045/74)were trans-
fected into BRPC and stimulated with insulin (100 nM; Fig. 4A)
or H2O2 (50 M; Fig. 4B). These data are presented as fold
induction of promoter activity compared with HO-1-(4045/
74) promoter construct in the absence of insulin or H2O2.
Induction by insulin or H2O2 was similar to construct HO-1-
(4045/74) in deletion mutants 3524 and 2986/74 of
HO-1. In contrast, deletions (including constructs HO-1-
(2413/74), HO-1-(1857/74), HO-1-(295/74),
HO-1-(137/74), HO-1-(117/74), HO-1-(66/74),
and HO-1-(34/74)) showed a significant reduction in pro-
moter activity when exposed to insulin (Fig. 4A) or H2O2 (Fig.
4B). These results suggest that critical elements for HO-1
induction by either insulin or H2O2 in the BRPC are located
FIGURE1.HO-1expression in retinalvascular cells inducedby insulin.A, BREC, BRPC, andBRPEwere treated
with low glucose (5.6mM), HG (25mM) for 24 h, insulin (100 nM) for 6 h. B, intravitreous injection of saline (right
eye) or insulin (10 l of 100 nM; left eye) for 24 h in Sprague-Dawley rat retina (n 6). Expression of HO-1 was
detected by Western blot analyses and normalized with actin expression. One experiment representative of
three immunoblots is shown with densitometric quantitation (means S.D.) from three independent exper-
iments. *, p 0.05 versus PBS-treated cells.
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downstream of bp2986 to3524 and upstream to2413 in
the HO-1 promoter. Further analysis showed that N-acethyl
cysteine, a potent antioxidant, did not prevent insulin actions
on HO-1 mRNA expression (Fig. 5) but did prevent the activa-
tion of H2O2, suggesting that themechanism and the promoter
elements are different between insulin and H2O2.
IRS1/PI3K/Akt2 Serves as a Downstream Signaling Target for
the Action of Insulin on HO-1 Expression—To characterize the
signaling pathway by which insulin was inducing HO-1 expres-
sion, we pretreated BRPC with spe-
cific inhibitors of PI3K, ERK, and
p38 MAPK pathway. As expected,
insulin exposure for 3 h increased
HO-1mRNA expression by 3.9-fold
(p  0.05) as compared with
untreated cells.When the cells were
pretreated with PI3K inhibitors,
wortmannin, or LY294002, the
effect of insulin onHO-1 expression
was completely abrogated (Fig. 6A).
In contrast, inhibitors of ERK and
p38 MAPK did not affect insulin
action on HO-1 mRNA expression
(Fig. 6A). These results suggested
that insulin induced HO-1 expres-
sion through activation of PI3K
pathway. To determine the role of
specific Akt in insulin action on
HO-1 expression, we overexpressed
adenoviral vector of control LacZ
or dominant negative construct
of Akt. The results showed that
control LacZ-overexpressed cells
responded identically to insulin-in-
duced HO-1 mRNA expression as
nontransfected cells. However,
overexpression of an adenoviral
vector containing dominant nega-
tive ofAkt in BRPC inhibited insulin
action by 95% (p 0.05) to promote
HO-1 expression (Fig. 6B). Trans-
fection of BRPCwith specific siRNA
of Akt1 and Akt2 reduced protein
expression of Akt1 and Akt2 by 65
and 75%, respectively (Fig. 7A).
Using the same siRNA of Akt1 and
Akt2 to reduce their protein expres-
sions, we were able to demonstrate
that increased HO-1 expression by
exposure of insulin for 12 hwas only
abrogated significantly in Akt2
siRNA transfected cells by 100%
(p  0.05) as compared with GFP
control but not with Akt1 siRNA
transfected cells (Fig. 7A). These
results indicated that insulin pro-
motes HO-1 expression via activa-
tion of Akt2 signaling pathway. In
another set of experiments, we overexpressedwild-type IRS1 or
IRS2 adenoviral vector in the pericytes. The results showed that
overexpression of IRS1, but not IRS2, further increased HO-1
protein expression by insulin (Fig. 7A) and also prevented com-
pletely H2O2-induced pro-apoptoticmarkers such as caspase-8
and BAX expression (p 0.05) (Fig. 7B). Insulin, via IRS1 acti-
vation, increased the phosphorylation of Bad by 3-fold (p 
0.01), which will bind to BAX and consequently prevent BAX
association to Bcl-2. Interestingly, the overexpression of IRS1
FIGURE 2. Time- anddose-dependent effect of insulin onHO-1mRNAandprotein expression. BRPCwere
treated with insulin in a time- (A and B) and dose-dependent manner (C and D). HO-1 (black bars) and HO-2
(white bars) protein (A and C) and mRNA (B and D) expressions were measured by Western blot and RT-PCR
analyses and normalized either by actin or 18 S expression. The experiments were done in triplicate, and one
experiment representative of three immunoblots is shown with densitometric quantitation (means  S.D.)
from three separate experiments. *, p 0.05 versus PBS-treated cells.
FIGURE 3. Insulin regulatedHO-1 transcriptional andpromoter activity. BRPCwere stimulatedwith insulin
(100 nM) for 3 hwith orwithout actimomycinD (5g/ml). HO-1mRNAexpressionwas evaluated by RT-PCR (A).
BRPC were transiently transfected with luciferase reporter plasmid HO-1-(4045/74) (250 ng/well). After
transfection, the cells were treated with vehicle or insulin (100 nM) for 24 h and then harvested for luciferase
assay. The luciferase activity was plotted as fold induction comparedwith activity of HO-1-(4045/74) with-
out insulin treatment (B). More than three independent experiments were performed. *, p 0.05 versus PBS-
treated cells; †, p 0.05 versus insulin.
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and IRS2 enhanced the phosphorylation of Akt and ERK simi-
larly, unlike their actions to HO-1 expression, suggesting that
the differentiation of insulin signaling to regulate HO-1 occurs
in steps downstream from Akt activation.
Insulin Prevents DNA Fragmentation and NF-B Binding
Activity Induced by H2O2 in BRPC—Oxidative stress has been
implicated in the apoptosis of BRPC in diabetes. Because insu-
lin can increase the expression of HO-1, we evaluated the
effects of insulin to prevent DNA fragmentation when exposed
to H2O2 in pericytes. As compared
with untreated cells, insulin did not
affect pericyte apoptosis at the basal
state (Fig. 8A). Exposure of pericyte
to H2O2 increased DNA fragmenta-
tion by 2.2-fold (p  0.001) (Fig.
8A). Stimulation with insulin prior
to H2O2 treatment prevented
H2O2-induced pericyte apoptosis in
BRPC by 96% (p 0.001). The anti-
apoptotic effects of insulin are
dependent to PI3Kpathway because
pretreatment of BRPC with wort-
mannin blocked insulin inhibitory
actions by 99% (p  0.001) on peri-
cyte apoptosis induced by H2O2
(Fig. 8A). Inhibition of HO-1 alone
increased DNA fragmentation in
nonstimulated cells and exacer-
bated H2O2 effects (2.86-fold; p 
0.001) while completely preventing
insulin action (Fig. 8A). Overex-
pression of IRS1 confirmed previ-
ous findings and diminished pro-apoptotic marker expression.
IRS1-overexpressed cells exhibited significant reduction, when
exposed to H2O2 alone or with insulin, in DNA fragmentation
as compared with control GFP-overexpressed cells by 102 and
105%, respectively (p  0.05) (Fig. 8B). No significant change
was noted in IRS2-overexpressed cells as compared with con-
trol GFP (Fig. 8B). In oxidative stress conditions, NF-B has
been shown to up-regulate many pro-apoptotic molecules. In
our studies, we demonstrated that control GFP-overexpressed
cells, exposed to H2O2, exhibited increases of NF-B binding
activity by 5.31-fold (p  0.001) (Fig. 9). Insulin-decreased
NF-B binding activity induced by H2O2 by 55% (p 0.05). In
IRS1-overexpressed cells, the capacity of H2O2 to increase
NF-Bwas reduced by 63% as comparedwith controlGFP cells.
Furthermore, insulin treatment completely prevented H2O2-
induced NF-B action (p  0.01) (Fig. 9). In contrast, overex-
pression of IRS2 by Ad-IRS2 did not differ significantly from
cells injected with Ad-GFP.
DISCUSSION
Reactive oxygen species, which are produced as by-products
of normal metabolism, are capable of causing cellular damage,
leading to cell death and tissue injury. Mammalian cells are
equipped with both enzymatic and nonenzymatic antioxidant
defense mechanisms to minimize the cellular damage resulting
from interactions between cellular constituents and ROS (40).
Diabetic patients have a high risk of developing vascular dis-
eases. Hyperglycemia leads to significant cellular metabolic
changes, which are postulated to initiate the sequence of events
causing pathological changes, partly because of oxidative stress
in the small vessels (41). Clinical studies have clearly demon-
strated that intensive glycemic control by insulin and other
medical interventions can reduce major microvascular events
in diabetes (7). In addition to normalizing glycemic control,
there is a great deal of data supporting the idea that insulin has
FIGURE 4. Insulin responsive site of HO-1 promoter is located downstream of bp 2986. BRPC were
transiently transfected with deletion mutants of the HO-1 promoter (250 ng/well). After the transfection, the
cellswere treatedwith insulin (A, 100nM) orH2O2 (B, 50M) for 24hand thenharvested.HO-1promoter activity
was calculated by comparison with the HO-1-(4045/74) promoter construct. *, p 0.05 versus activity of
HO-1-(4045/74) promoter construct stimulated with either insulin or H2O2 treatment in three separate
experiments.
FIGURE 5.HO-1mRNA expression induced by insulin is not prevented by
antioxidant. BRPC were treated with insulin (100 nM) for 3 h with or without
N-acethyl cysteine (20mM). HO-1mRNA expressionwasmeasured by RT-PCR
analyses and normalized by 18 S expression. The experiments were done in
triplicate, and the data are expressed as the means S.D. *, p 0.05 versus
PBS-treated cells.
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direct vasotropic actions. The aim of our study was to investi-
gate whether insulin mediates some of its vasotropic actions by
regulating the expression of antioxidant molecules HO-1 and
prevents cellular apoptosis induced by oxidants such as H2O2.
HO-1 expression is commonly elevated in oxidative and
inflammatory environment (19, 25). An overwhelming body of
evidence indicates that the heme-HO system is intrinsically
involved in the regulation of many physiological and patho-
physiological processes, including diabetes (27, 28). Hypergly-
cemia may also enhance retinal ROS production causing cell
damage and death. In our study, exposure of HG in retinal vas-
cular cell only increased HO-1 expression in BREC but not in
BRPE or BRPC. Many factors can explain these results. HG-
induced oxidants and elevation of HO-1 expression response in
EC occurred generally within a short exposure as compared
with BRPE or BRPC. In our study, we only exposed cells for 18 h
with HG. It is believed that the majority of metabolic changes
induced byHG in pericytes require longer exposure (more than
3 days).4 However, it is also possible that these data suggest
there are differences in the amount of ROS being generated in
BRPE and BRPC versus BREC, indicating the importance of
oxidative stress as an inciting factor for vascular diseases in
diabetes that may be cell-dependent. These results have pro-
vided strong support that insulin can regulate HO-1 in a phys-
iological manner. Insulin significantly increased HO-1 protein
expression in retina after intravitreous injection and in all reti-
nal vascular cells (BREC, BRPE, and BRPC). Interestingly, insu-
lin was previously reported to not only activate NO formation
but also to enhance expression of ferritin, a secondary antioxi-
dant protein that is often induced in tandem with HO-1 (22).
Insulin has been reported to induce HO-1 expression in renal
cells. Other growth factors such as transforming growth fac-
tor-, but not basic fibroblast growth factor, platelet-derived
growth factor, transforming growth factor-, insulin-like
growth factor-1, and epidermal growth factor, have been
reported to increase HO-1 mRNA
and protein expression in BRPE in a
time- and dose-dependent manner
(42). Our findings characterized
insulin action on HO-1 regulation
in detail, demonstrating that insulin
increased HO-1 mRNA and protein
expression in BRPC in a time- and
dose-dependent manner with max-
imum effects at 3 and 12 h, respec-
tively, without affecting HO-2
mRNA and protein expression. A
question can also be raised regard-
ing the physiological importance of
insulin actions because most of the
cellular studies were performed
using 100 nM. However, the expres-
sion studies of HO-1 required incu-
bation times of 3–10 h, which may
allow most of the insulin in the
media to degrade. Multiple lines of
data support insulin action to increase HO-1 expression as
being physiologically important. The effect of insulin was sig-
nificant at 1 nM, clearly indicating again the physiological
importance of the findings, which has been confirmed by the
intravitreous injection studies. The increase of HO-1 induced
by insulin is also comparable with HG levels andH2O2 (50M),
which again supports the postulate that this effect of insulin is
both biologically and physiologically significant.
In contrast to HO-2, HO-1 is regulated at the gene transcrip-
tion level. Two enhancer regions located 4 and 10 kb upstream
from the transcription start site have been shown to play a role
in the induction ofHO-1byLPS inmacrophages (43).However,
deletion of the10 kb enhancer does not decrease HO-1 pro-
moter activity; instead it further increases its activity in the
presence of the4kb enhancer only, suggesting that some neg-
ative regulatory elements are present in the upstream region of
HO-1 (44). Therefore, we focused our interest in the 4-kb
enhancer region of the HO-1 promoter. Luciferase assay
showed that insulin induced HO-1 (4045/74) promoter
activity by 3-fold (Fig. 3B). Transfection of deletion constructs
removing the4 kb enhancer region did not show a reduction
in promoter activity after stimulation with insulin or H2O2 in
BRPC. In fact, the deletion mutants down to construct HO-1-
(2986/74) maintained an activity analogous to that con-
struct HO-1-(4045/74), which exhibited the greatest
response to insulin. Further deletion constructs (HO-1-
(2413/74), HO-1-(1857/74), HO-1-(295/74),
HO-1-(137/74), HO-1-(117/74), HO-1-(66/74),
and HO-1-(34/74)) showed a significant reduction in pro-
moter activitywhen exposed to both insulin andH2O2.Analysis
of the promoter sequence revealed that stress-responsive ele-
ments, which are present in multiple copies in murine enhanc-
ers (3885/3876; 3937/3928; 3983/3974) and spa-
tially and structurally well conserved among mouse, rat, and
human ho-1 genes, are functionally similar to antioxidant
response elements (23). Previous studies demonstrated that
NF-E2-related factor 2 (Nrf2) regulates induction of HO-1 by4 P. Geraldes and G. L. King, unpublished observations.
FIGURE 6. PI3K serves as a downstream target for insulin on HO-1 mRNA expression. BRPC were treated
with insulin (100 nM) for 3 h with or without PI3K inhibitors (wortmannin and LY294002), ERK inhibitor
(PD98059), or p38 MAPK inhibitor (SB203580) (A). The cells were infected with adenoviral vector of Akt domi-
nant negative or LacZ control and then stimulated with insulin (100 nM) for 3 h. HO-1 mRNA expression was
measuredbyRT-PCR analyses andnormalizedby 18 S expression. The experimentswere done in triplicate, and
the data are expressed as the means S.D. *, p 0.05 versus PBS-treated cells; †, p 0.05 versus insulin.
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stimuli such as heme and antioxidants (45). However, in our
data, insulin-induced HO-1 promoter activity may not corre-
spond to the same response element as Nrf2 because insulin
action on HO-1 mRNA expression remained unaffected by the
use of the antioxidant N-acethyl cysteine. This finding is in
contrast to previous reports supporting the possibility thatNrf2
is a potential transcriptional factor for insulin-promoted HO-1
in renal cells (46). Factors such as the cell type, dose used, and
timeof exposuremay explain the difference betweenour results
and previous studies. Clearly, our
studies were not precise enough to
identify the 5 DNA-responsive ele-
ment or to show that Nrf2 is not
involved. More precise and detailed
studies will be needed to identify the
responsive element for insulin in the
region of HO-1.
The mechanisms by which insu-
lin promotes HO-1 levels in peri-
cytes were further analyzed using
PI3K/Akt, ERK, and p38 MAPK
inhibitors because these signaling
pathways have been reported to reg-
ulate HO-1 induction. A previous
report observed that the PI3K path-
way mediates HO-1 expression by
carnosal, a polyphenol isolated from
the herb rosemary (33, 45). It is
reported that oxidative stress can
activate MAPK pathways to induce
the ho-1 gene. Cadmium, a stress
inducer compound, enhanced
HO-1 levels that involve p38MAPK
activity (47). Moreover, inhibition
of p38MAPK reducesHO-1 expres-
sion following carnosal (45) and
diallyl sulfide treatment (48),
although an earlier study found that
p38 inhibition had no effect on
HO-1 mRNA expression following
cadmium, arsenate, or hemin treat-
ment (49). Our results showed that
inhibition of PI3K/Akt pathway, but
not the ERK or p38 MAPK cascade,
prevents insulin action on HO-1
expression in BRPC. Further, using
specific siRNA of Akt1 and Akt2 to
knock down the expressions of each
Akt isoforms, we demonstrated for
the first time that insulin induced
HO-1 expression selectively via
Akt2 isoform. Even more interest-
ingly, in addition to Akt2, insulin
action to increase HO-1 expression
in retinal pericytes is also selective
for IRS1 but not for IRS2. However,
the effects of insulin on the phos-
phorylate for Akt and ERK were
enhanced equally among control of Ad-IRS1- or 2-infected
cells. Differentiation of IRS1 and IRS2 actions on HO-1 expres-
sion and apoptosis appears to occur after the activation of Akt
because both were able to increase the activation of Akt equally
in pericytes. The exhibition of differential effects between IRS1
and IRS2 occurs in many types of cells including liver, retina,
brain, and others (53, 54). IRS1 appears to mediate rapid met-
abolic actions in the cells, whereas IRS2 may mediate more
prolonged actions of the cells (53, 54). It is possible that the
FIGURE 7. HO-1 expression induced by insulin is mediated through IRS1/Akt2 isoform. BRPC were trans-
fected with specific Akt1, Akt2, siRNAs, Ad-IRS1, Ad-IRS2, or control siRNAs and GFP adenovirus, treated in the
presence or absence of 100 nM of insulin for 12 h and then exposed to H2O2 (50M) for 1 h as described under
“Experimental Procedures.” The expression of HO-1, Akt-1, Akt-2, phospho-Akt, phospho-ERK (A), IRS1, IRS2,
caspase-8, BAX, andphospho-Bad (B)wasdetectedbyWesternblot analyses andnormalizedwith actin expres-
sion. One experiment representative of three immunoblots is shown with densitometric quantitation
(means S.D.) from three separate experiments. *, p 0.05 versus PBS-treated cells.
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differential effects of IRS1 and IRS2 on HO-1 expression could
be due to differences in subcellular location of the signaling
pathways induced by the second messengers of insulin recep-
tors in the pericytes. Further studies will be needed to identify
the post-Akt steps, which are differentially activated by IRS1/2
to cause the changes inHO-1 and apoptosis in pericytes. Insulin
dose of 100 nM could also activate the insulin-like growth fac-
tor-1 receptor. However, our data clearly indicate that IRS1
involvement suggests that insulin is the mediator of HO-1
induction in our model.
HO-1 has been described as a protein capable of cytoprotec-
tion via radical scavenging and apoptosis prevention. The up-
regulation of HO-1 to promote survival of Mueller cells after
ischemia-reperfusion injury has been reportedly caused by
decreasing infiltration of inflammatory cells and destruction of
the retina (50). Thus, insulin action on HO-1 induction may
represent a potential mechanism to prevent pericyte loss. Our
data showed that exposure to oxidant generator H2O2
increased DNA fragmentation in pericytes. Treatment with
insulin abrogated the effect of H2O2 on pericyte apoptosis, and
these beneficial actions of insulin are also mediated via IRS1/
PI3K/Akt1 pathway and HO-1. Previous work demonstrated
that insulin possessed free radical scavenging properties pre-
serving the integrity of the vascular wall because of its capac-
ity to protect cardiomyocytes from the deleterious effects of
H2O2 (51). Because intensive glycemic treatment in clinical
trials using insulin can delay the progression of retinopathy
and other microvascular pathologies in type 1 diabetic
patients, the loss of the direct vasotropic actions of insulin
may increase the risks of developing retinal disease in type 1
diabetic patients (52). Thus, our results suggest the possibil-
ity that the beneficial effect of insulin may be attributed to its
capacity to increase HO-1 expression to prevent excessive
cellular apoptosis of pericytes, an early and specific his-
topathological finding of diabetic retinopathy.
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